Showing results (111-120 of 759) with videos related to
Sort By:
Pageof 76
Acta Diabetologica|October 14, 2021
Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trialFabiola Carrara, Piero Ruggenenti, Annalisa Perna, et al.Journal of Ophthalmology|July 15, 2010
Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trialPiero Ruggenenti, Ilian Iliev, Marco Filipponi, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2016
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver DiseaseAntonio Pisani, Massimo Sabbatini, Massimo Imbriaco, et al.Journal of the American Society of Nephrology : JASN|May 11, 2017
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous NephropathyJan A J G van den Brand, Piero Ruggenenti, Antonietta Chianca, et al.Journal of the American Society of Nephrology : JASN|May 28, 2009
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcomeDario Cattaneo, Piero Ruggenenti, Sara Baldelli, et al.Journal of the American Society of Nephrology : JASN|February 3, 2023
Intensive BP Control in Patients with CKD and Risk for Adverse OutcomesElaine Ku, Charles E McCulloch, Lesley A Inker, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2023
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort StudyPiero Ruggenenti, Linda Reinhard, Barbara Ruggiero, et al.Journal of the American Society of Nephrology : JASN|March 26, 2015
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous NephropathyPiero Ruggenenti, Hanna Debiec, Barbara Ruggiero, et al.Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.Plos One|July 17, 2024
GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniquesFabiola Carrara, Flavio Gaspari, Matias Trillini, et al.Pageof 76